Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：1
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [41] Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    Zhou, Zhou
    Tang, Derek H.
    Xie, Jipan
    Ayyagari, Rajeev
    Wu, Eric
    Niravath, Polly A.
    ADVANCES IN THERAPY, 2017, 34 (12) : 2566 - 2584
  • [42] Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2-advanced breast cancer
    Jhaveri, Komal
    O'Shaughnessy, Joyce
    Fasching, Peter A.
    Tolaney, Sara M.
    Yardley, Denise A.
    Sharma, Vikash Kumar
    Biswas, Chandroday
    Thuerigen, Astrid
    Pathak, Purnima
    Rugo, Hope S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [43] Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
    Porte, B.
    Carton, M.
    Lerebours, F.
    Brain, E.
    Loirat, D.
    Haroun, L.
    Bellesoeur, A.
    Hamba, S. Bach
    Kirova, Y.
    Cottu, P.
    BREAST, 2020, 54 : 303 - 310
  • [44] Risks and benefits from CDK inhibitors for advanced HR+ Her 2-breast cancer
    Messina, C.
    Messina, M.
    Zanardi, E.
    ANNALS OF ONCOLOGY, 2017, 28 (12) : 3099 - 3100
  • [45] Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2-advanced breast cancer in the randomized MONALEESA-2 trial
    O'Shaughnessy, Joyce
    Petrakova, Katarina
    Sonke, Gabe S.
    Conte, Pierfranco
    Arteaga, Carlos L.
    Cameron, David A.
    Hart, Lowell L.
    Villanueva, Cristian
    Jakobsen, Erik
    Beck, Joseph T.
    Lindquist, Deborah
    Souami, Farida
    Mondal, Shoubhik
    Germa, Caroline
    Hortobagyi, Gabriel N.
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (01) : 127 - 134
  • [46] Cost-effectiveness of CDK4/6 inhibitors for second-line HR+/HER2-advanced or metastatic breast cancer in China
    Jia, Caifeng
    Zhang, Sen
    Wang, Jie
    Feng, Bing
    Shi, Fenghao
    Wang, Meiqi
    Li, Sainan
    Xu, Hao
    Wang, Mingxia
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [47] Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study
    Joanne L. Blum
    Caroline DiCristo
    David Gordon
    Meghan S. Karuturi
    David Oubre
    Erin Jepsen
    Juan Cuevas
    Shailendra Lakhanpal
    Monica Z. Montelongo
    Zhe Zhang
    Joseph C. Cappelleri
    Yao Wang
    Debu Tripathy
    Breast Cancer Research and Treatment, 2024, 203 : 463 - 475
  • [48] Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2-Advanced Breast Cancer
    Patel, Ram
    Mathews, John
    Hamm, Caroline
    Kulkarni, Swati
    Gupta, Rasna
    Opperman, Tarquin
    Chiong, John Dean
    Nasser, Abdullah
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [49] Quality of life with ribociclib versus abemaciclib as first-line treatment of HR+/HER2-advanced breast cancer: a matching-adjusted indirect comparison
    Rugo, Hope S. S.
    Harmer, Victoria
    O'Shaughnessy, Joyce
    Jhaveri, Komal
    Tolaney, Sara M. M.
    Cardoso, Fatima
    Bardia, Aditya
    Maheshwari, Vikalp Kumar
    Tripathi, Sandeep
    Haftchenary, Sina
    Pathak, Purnima
    Fasching, Peter A. A.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [50] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer
    Anand A. Dalal
    Patrick Gagnon-Sanschagrin
    Rebecca Burne
    Annie Guérin
    Geneviève Gauthier
    Tania Small
    Polly Niravath
    Advances in Therapy, 2018, 35 : 768 - 778
12345